Kyushu University Academic Staff Educational and Research Activities Database
Researcher information (To researchers) Need Help? How to update
Eiichi Ogawa Last modified date:2019.11.25

Assistant Professor / Department of Environmental Medicine and Infectious Disease
Department of Clinical Medicine
Faculty of Medical Sciences


Graduate School


E-Mail
Phone
092-642-5909
Fax
092-642-5210
Academic Degree
PhD in medicine
Field of Specialization
general internal medicine、clinical infection、hepatology
Research
Research Interests
  • Large cohort study of chornic liver diseases
    keyword : chronic liver disease、wide area network
    2010.08.
  • The evaluation of the effect of interferon or interferon-free treatment according to IL28B and ITPA polymorphism in patients with chorinic hepatitis C
    keyword : interleukin 28B、hepatitis C
    2010.08.
  • The clinical evaluation of liver stiffness using transient elastography in patients with chronic hepatitis C and B.
    keyword : viral hepatitis, liver fibrosis
    2007.01.
Academic Activities
Reports
1. Ogawa E, Furusyo N, Nguyen MH, Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy, Drug Design, Development and Therapy, 10.2147/DDDT.S126742, 2017.11.
2. Eiichi Ogawa, Norihiro Furusyo, Jun Hayashi, Commentary: Triple therapy for patients with chronic hepatitis C and advanced fibrosis? Authors' reply., Alimentary Pharmacology and Therapeutics, 2013.12.
3. Eiichi Ogawa, Norihiro Furusyo, Jun Hayashi, Reply to: "Lower incidence of hepatocellular carcinoma in patients with transient virologic response to peginterferon and ribavirin combination therapy: Is it really the effect of the therapy?" , Journal of Hepatology, 2013.04.
4. Ogawa E, Murata M, Unno M, Otaguro S, Kainuma M, Sawayama Y, Furusyo N, Yanai S, Matsumoto T, Hayashi J., Protein-losing enteropathy during highly active antiretroviral therapy in a patient with AIDS-related disseminated Mycobacterial avium complex infection., Journal of Infection and Chemotherapy, 2009.08.
5. Ogawa E, Otaguro S, Murata M, Kainuma M, Sawayama Y, Furusyo N, Hayashi J., Intravenous immunoglobulin therapy for severe arthritis associated with human parvovirus B19 infection., Journal of Infection and Chemotherapy, 2008.10.
Papers
1. Ogawa E, Furusyo N, Nakamuta M, Nomura H, Satoh T, Takahashi K, Koyanagi T, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Kato M, Shimoda S, Hayashi J, Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study, Hepatology Research, 10.1111/hepr.13328, 49, 6, 617-626, 2019.06.
2. Eiichi Ogawa, Norihiro Furusyo, Koichi Azuma, Makoto Nakamuta, Hideyuki Nomura, Kazufumi Dohmen, Takeaki Satoh, Akira Kawano, Toshimasa Koyanagi, Aritsune Ooho, Kazuhiro Takahashi, Masaki Kato, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi, Elbasvir plus Grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease, Antiviral Research, 10.1016/j.antiviral.2018.10.003, 159, 143-152, 2018.11.
3. Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, Takahashi K, Kawano A, Azuma K, Satoh T, Nakamuta M, Koyanagi T, Kato M, Shimoda S, Kajiwara E, Hayashi J, Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment, ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 10.1111/apt.14380, 47, 1, 104-113, 2018.01.
4. Ogawa E, Furusyo N, Murata M, Toyoda K, Hayashi T, Ura K, Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV, LIVER INTERNATIONAL, 10.1111/liv.13496, 38, 1, 76-83, 2018.01.
5. Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazufumi Dohmen, Nobuhiko Higashi, Kazuhiro Takahashi, Akira Kawano, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta, Toshimasa Koyanagi, Masaki Kato, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi, NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b, Journal of Gastroenterology, 52, 7, 845-854, 2017.07.
6. Eiichi Ogawa, Norihiro Furusyo, Masayuki Murata, Motohiro Shimizu, Toyoda Kazuhiro, Taeko Hotta, Takeshi Uchiumi, Jun Hayashi, Comparison of the Abbott RealTime HCV and Roche COBAS Ampliprep/COBAS TaqMan HCV assays for the monitoring of sofosbuvir-based therapy, Antiviral Therapy, 10.3851/IMP3085, 22, 1, 61-70, 2017.03.
7. Eiichi Ogawa, Norihiro Furusyo, Naoki Yamashita, Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Makoto Nakamuta, Takeaki Satoh, Hideyuki Nomura, Koichi Azuma, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi, Effectiveness and safety of daclatasvir plus asunaprevir for HCV genotype 1b patients aged 75 and over with or without cirrhosis, Hepatology Research, doi: 10.1111/hepr.12738, 47, 3, E120-E131, 2017.03.
8. Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazuhiro Takahashi, Nobuhiko Higashi, Akira Kawano, Kazufumi Dohmen, Takeaki Satoh, Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi, Masaki Kato, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi, Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis, Antiviral Research, 24, 136, 37-44, 2016.12.
9. Eiichi Ogawa, Norihiro Furusyo, Murata Masayuki, Takeo Hayashi, Motohiro Shimizu, Haru Mukae, Kazuhiro Toyoda, Taeko Hotta, Takeshi Uchiumi, Jun Hayashi, Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy, Antiviral Research, 126, 35-42, 2016.02.
10. Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Hideyuki Nomura, Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Takeaki Satoh, Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection, Journal of Gastroenterology and Hepatology, 30, 12, 1759-1767, 2015.12.
11. Eiichi Ogawa, Norihiro Furusyo, Kazufumi Dohmen, Eiji Kajiwara, Akira Kawano, Hideyuki Nomura, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure, Journal of Viral Hepatitis, 22, 12, 992-1001, 2015.12.
12. Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Hideyuki Nomura, Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Takeaki Satoh, Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Comparative safety study on severe anemia by simeprevir- versus telaprevir-based triple therapy for chronic hepatitis C, Journal of Gastroenterology and Hepatology, doi: 10.1111/jgh.12945., 30, 8, 1309-1316, 2015.08.
13. Eiichi Ogawa, Norihiro Furusyo, Motohiro Shimizu, Takeshi Ihara, Takeo Hayashi, Yuji Harada, Kazuhiro Toyoda, Murata Masayuki, Jun Hayashi, Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C, ANTIVIRAL THERAPY, 20, 185-192, 2015.05.
14. Eiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Akira Kawano, Yuichi Tanabe, Kazuhiro Kotoh, Shinji Shimoda, Tomohiko Akahoshi, Yoshihiko Maehara, Jun Hayashi, Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis, Journal of Gastroenterology and Hepatology, 29, 1728-1735, 2014.09.
15. Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Makoto Nakamuta, Koichi Azuma, Akira Kawano, Yuichi Tanabe, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection, Antiviral Research, 104, 102-109, 2014.04.
16. Eiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Akira Kawano, Yuichi Tanabe, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: A prospective clinical study , Alimentary Pharmacology and Therapeutics, 38, 9, 1076-1085, 2013.11.
17. Eiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Akira Kawano, Yuichi Tanabe, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy, Journal of Hepatology, 59, 4, 667-674, 2013.09.
18. Eiichi Ogawa, Norihiro Furusyo, Murata Masayuki, Kazuhiro Toyoda, Kunimitsu Eiraku, Motohiro Shimizu, Yuji Harada, Fujiko Mitsumoto, Koji Takayama, Okada Kyoko, Mosaburo Kainuma, Jun Hayashi, Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: A comparison of two real-time PCR assays, Antiviral Research, 99, 2, 119-124, 2013.08.
19. Eiichi Ogawa, Norihiro Furusyo, Murata Masayuki, Hiroaki Ikezaki, Takeshi Ihara, Takeo Hayashi, Kazuhiro Toyoda, Okada Kyoko, Mosaburo Kainuma, Eiji Kajiwara, Kazuhiro Takahashi, Takeaki Satoh, Jun Hayashi, Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia, Journal of Viral Hepatitis, 20, 12, 838-846, 2013.12.
20. Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Toshihiro Maruyama, Yuichi Tanabe, Takeaki Satoh, Makoto Nakamuta, Kazuhiro Kotoh, Koichi Azuma, Kazufumi Dohmen, Shinji Shimoda, Jun Hayashi, Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: A prospective, multicenter study, Journal of Hepatology, 58, 3, 495-501, 2013.03.
21. Ogawa E, Furusyo N, Murata M, Ikezaki H, Ihara T, Hayashi T, Toyoda K, Taniai H, Okada K, Kainuma M, Hayashi J, Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1, Journal of Hepatology, 57, 3, 534, 2012.09.
22. Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Yuichi Tanabe, Takeaki Satoh, Toshihiro Maruyama, Makoto Nakamuta, Kazuhiro Kotoh, Koichi Azuma, Kazufumi Dohmen, Shinji Shimoda, Jun Hayashi, An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin., Journal of Infection and Chemotherapy, DOI: 10.1007/s10156-012-0396-5, 18, 5, 689-697, 2012.10.
23. Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; The Kyushu University Liver Disease Study (KULDS) Group., An evaluation of the adverse effect of premature discontinuation of pegylated interferon alpha-2b and ribavirin treatment for chronic hepatitis C virus infection: Results from Kyushu University Liver Disease Study (KULDS), Journal of Gastroenterology and Hepatology, 27, 7, 1233-1240, 2012.07.
24. Ogawa E, Furusyo N, Murata M, Ohnishi H, Toyoda K, Taniai H, Ihara T, Ikezaki H, Hayashi T, Kainuma M, Hayashi J., Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog, Hepatology Research, 41, 12, 1178-88, 2011.12.
25. Ogawa E, Furusyo N, Toyoda K, Taniai H, Otaguro S, Kainuma M, Murata M, Sawayama Y, Hayashi J., Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b and ribavirin treatment., BMC Gastroenterology, 10, 38, 2010.04.
26. Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J., The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients with treated with pegylated interferon alpha-2b and ribavirin., Antiviral Research, 83, 2, 127-134, 2009.04.
27. Ogawa E, Furusyo N, Toyoda K, Takeoka H, Otaguro S, Hamada M, Murata M, Sawayama Y, Hayashi J., Transient elastography for patients with chronic hepatitis B and C virus infection: A noninvasive, quantitative assessment of liver fibrosis., Hepatology Research, 37, 12, 1002-1010, 2007.12.
Presentations
1. Eiichi Ogawa, Hidenori Toyoda, Etsuko Iio, Masaru Enomoto, Shinji Iwane, Toshifumi Tada, Satoshi Yasuda, Hirokazu Takahashi, Yuichiro Eguchi, Yoshiyuki Ueno, Akihiro Tamori, Norihiro Furusyo, Yasuhito Tanaka, Mindie H. Nguyen, SVR to DAA therapy in active HCC, inactive HCC, and non-HCC HCV patients: A propensity score matched study from the Asia Liver Consortium, 第23回日本肝臓学会大会 (JDDW 2019), 2019.11.
2. Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Makoto Nakamuta, Akira Kawano, Takeaki Satoh, Aritsune Ooho, Koichi Azuma, Toshimasa Koyanagi, Eiji Kajiwara, Yasunori Ichiki, Masami Kuniyoshi, Kimihiko Yanagita, Hiromasa Amagase, Chie Morita, Rie Sugimoto, Shinji Shimoda, Masaki Kato, Jun Hayashi, Incidence of hepatocellular carcinoma and mortality after HCV elimination by all-oral DAA therapy: Results from a large-scale, multicenter cohort study, 54th Annual Meeting of the European Association Study of the Liver (EASL) , 2019.04.
3. Eiichi Ogawa, Donghak Jeong, Yee Hui Yeo, Linda Henry, Sally Tran, Ramsey C. Cheung, Norihiro Furusyo, Mindie H Nguyen, Estimations of the total number of undiagnosed patients and antiviral treatment rate for chronic hepatitis B in the United States, The Liver Meeting (AASLD) 2018 , 2018.11.
4. Eiichi Ogawa, Etsuko Iio, Dae Won Jun, Chung-Feng Huang, Hiroaki Haga, Masaru Enomoto, Shinji Iwane, Dong Hyun Lee, Grace L.H. Wong, Hirokazu Takahashi, Hwai-I Yang, Chia-Yen Dai, Jee-Fu Huang, Jun Hayashi, Hideyuki Nomura, Makoto Nakamuta, Mi Jung Jun, Norihiro Furusyo, Yasuhito Tanaka, Mei-Hsuan Lee, Sally Tran, Ming-Lung Yu, Akihiro Tamori, Yoshiyuki Ueno, Yuichiro Eguchi, Linda Henry, Mindie H. Nguyen, Effectiveness and safety of DAA treatment for chronic hepatitis C patients with previous hepatocellular carcinoma: Results from a real-world, multicenter study of Asian countries, The Liver Meeting (AASLD) 2018, 2018.11.
5. Eiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, Development of hepatocellular carcinoma after HCV eradiation following all-oral DAAs - Results from a multicenter study of KULDS -, 第22回日本肝臓学会大会 (JDDW 2018), 2018.11.
6. Eiichi Ogawa, Donghak Jeong, Yee Hui Yeo, Linda Henry, Sally Tran, Mindie H Nguyen, Estimating the number of undiagnosed patients and antiviral treatment rate for chronic hepatitis B in the United States using the Truven Health MarketScan Database, Digestive Disease Week in 2018, 2018.06.
7. Eiichi Ogawa, Donghak Jeong, Yee Hui Yeo, Mindie H Nguyen, Estimated the number of undiagnosed patients and antiviral treatment rate of chronic hepatitis B in the U.S. based on the Truven Health MarketScan Database, 53th Annual Meeting of the European Association Study of the Liver (EASL), 2018.04.
8. Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazufumi Dohmen, Nobuhiko Higashi, Kazuhiro Takahashi, Akira Kawano, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta, Toshimasa Koyanagi, Shinji Shimoda, Masaki Kato, Eiji Kajiwara, Jun Hayashi, Development of hepatocellular carcinoma following HCV eradication by direct-acting antivirals: Real-life experience from Japanese multicenter cohort, 53th Annual Meeting of the European Association Study of the Liver (EASL), 2018.04.
9. Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazufumi Dohmen, Nobuhiko Higashi, Kazuhiro Takahashi, Akira Kawano, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta, Toshimasa Koyanagi, Shinji Shimoda, Masaki Kato, Eiji Kajiwara, Jun Hayashi, Early development of hepatocellular carcinoma after hepatitis C virus eradication in interferon-free direct-acting antiviral treatment: Results from a real-life, multicenter study, The Liver Meeting 2017 (AASLD), 2017.10.
10. Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazufumi Dohmen, Nobuhiko Higashi, Kazuhiro Takahashi, Akira Kawano, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta, Toshimasa Koyanagi, Shinji Shimoda, Masaki Kato, Eiji Kajiwara, Jun Hayashi, Effectiveness and safety of sofosbuvir-based regimens for Japanese patients with HCV genotype 1b or 2 infection: Real life experience from a multicenter cohort, 52th Annual Meeting of the European Association Study of the Liver (EASL), 2017.04.
11. Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazufumi Dohmen, Nobuhiko Higashi, Kazuhiro Takahashi, Akira Kawano, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta, Toshimasa Koyanagi, Shinji Shimoda, Masaki Kato, Eiji Kajiwara, Jun Hayashi, Effectiveness of sofosbuvir-based regimens for Japanese patients with HCV genotype 1 or 2 infection: Real life experience from a multicenter cohort, The Asian Pacific Association for the Study of the Liver Single Topic Conference 2017, 2017.04.
12. Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazufumi Dohmen, Nobuhiko Higashi, Kazuhiro Takahashi, Akira Kawano, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta, Toshimasa Koyanagi, Shinji Shimoda, Masaki Kato, Eiji Kajiwara, Jun Hayashi, Effectiveness and safety of sofosbuvir plus ledipasvir for HCV genotype 1b patients with compensated cirrhosis, 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL 2017), 2017.02.
13. Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Naoki Yamashita, Kazufumi Dohmen, Akira Kawano, Kazuhiro Takahashi, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi, Effectiveness and safety of sofosbuvir and ribavirin for elderly patients with HCV genotype 2 infection, 51th Annual Meeting of the European Association Study of the Liver (EASL) , 2016.04.
14. Eiichi Ogawa, Norihiro Furusyo, Naoki Yamashita, Hideyuki Nomura, Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Takeaki Satoh, Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi, Efficacy of second-generation protease inhibitor-based triple therapy for HCV genotype 1b patients, The 25th Conference of the Asian Pacific Association for the Study of the Liver (APASL 2016) , 2016.02.
15. Eiichi Ogawa, Norihiro Furusyo, Masayuki Murata, Takeo Hayashi, Motohiro Shimizu, Haru Mukae, Kazuhiro Toyoda, Taeko Hotta, Takeshi Uchiumi, Jun Hayashi, Impact of HCV kinetics differs by the type of real-time assay used to monitor triple therapy, The 25th Conference of the Asian Pacific Association for the Study of the Liver (APASL 2016), 2016.02.
16. Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Hideyuki Nomura, Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Takeaki Satoh, Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Comparative study on the effectiveness of simeprevir or telaprevir in combination with peginterferon and ribavirin for chronic HCV genotype 1b infection, 50th Annual Meeting of the European Association Study of the Liver (EASL) , 2015.04.
17. Eiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Akira Kawano, Yuichi Tanabe, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Impact of the low-density lipoprotein cholesterol on response to telaprevir-based triple therapy for chronic hepatitis C patients, 49th Annual Meeting of the European Association Study of the Liver (EASL) , 2014.04.
18. Eiichi Ogawa, Norihiro Furusyo, Murata Masayuki, Hiroaki Ikezaki, Satoshi Hiramine, Jun Hayashi, Prediction and its management of severe anemia in chronic hepatitis C patients treated with telaprevir-based triple therapy, IDWeek 2013, 2013.10.
19. Eiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Akira Kawano, Yuichi Tanabe, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Impact of the viral kinetics of chronic hepatitis C patients treated with telaprevir in combination with pegylated interferon α2b and ribavirin, 48th Annual Meeting of the European Association Study of the Liver (EASL), 2013.04.